Evidence map›Paper›PMID 27046719›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2016

Presumptive treatment of multidrug-resistant tuberculosis in household contacts.

J B Parr, M L Rich, S Keshavjee, M F Franke, C D Mitnick, J Bayona, M C Becerra

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

J B ParrDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
M L RichPartners In Health, Boston, MA, USA; Lima, Peru; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
S KeshavjeePartners In Health, Boston, MA, USA; Lima, Peru; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
M F FrankePartners In Health, Boston, MA, USA; Lima, Peru; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
C D MitnickPartners In Health, Boston, MA, USA, and Lima, Peru; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
J BayonaPartners In Health, Boston, MA, USA, and Lima, Peru; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
M C BecerraPartners In Health, Boston, MA, USA, and Lima, Peru; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Global Health and Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02115, USA. mercedes_becerra@hms.harvard.edu.
University of North Carolina at Chapel Hill · US

Funding

Molecular epidemiology of drug-resistant tuberculosis in PeruK01HL080939 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BECERRA, MERCEDES C · 2005 to 2009
$680k
NHLBI NIH HHS K01 HL080939
6 · The paper itself

Abstract

settingMultidrug-resistant tuberculosis (MDR-TB) is a growing global health threat that often requires presumptive treatment in the absence of drug susceptibility testing (DST) results.

objectiveTo compare two approaches to the treatment of MDR-TB contacts with no DST results who develop TB disease.

designWe conducted a retrospective cohort study of adults treated for TB disease who were contacts of patients living with MDR-TB. Subjects had been treated according to one of two presumptive treatment strategies: 1) regimens containing exclusively first-line drugs, and 2) regimens that included both first- and second-line drugs that were adjusted if and when DST results became available. The primary endpoint was a composite of death and treatment failure.

resultsHousehold contacts of MDR-TB patients who developed TB disease and were treated with first-line regimens were significantly more likely to experience unfavorable end-of-treatment outcomes than those treated with presumptive MDR-TB regimens (RR 2.88, 95%CI 1.24-6.68).

conclusionHousehold contacts of MDR-TB patients who develop TB disease but have no DST results should receive regimens containing second-line drugs selected based on the infecting strain of the index patient. Regimens containing only first-line anti-tuberculosis drugs significantly increase the risk of unfavorable outcomes.

Indexed as

Family CharacteristicsAdultAntitubercular AgentsDrug Resistance, Multiple, BacterialEndpoint DeterminationFemaleHumansMaleMicrobial Sensitivity TestsMycobacterium tuberculosisPilot ProjectsRetrospective StudiesRisk FactorsSputumTreatment OutcomeTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID27046719
PMCPMC13650567
OpenAlexW2337444464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.